Howell A, Morrison J M, Bramwell V H, Harland R N, Moneypenny I J
Eur J Cancer Clin Oncol. 1984 Jul;20(7):873-6. doi: 10.1016/0277-5379(84)90157-3.
A combination of dibromodulcitol 500 mg orally, mitomycin C 10 mg i.v. and vinblastine 10 mg i.v. all given on day 1 and repeated every 4 weeks was given to 40 patients with advanced breast cancer. All but one had received previous endocrine therapy. The response rate (CR + PR) in 24 previously untreated patients was 66% and was 37% in 16 previously treated patients. The survival of responders was significantly longer than non-responders. Thirty-two per cent of patients experienced nausea and vomiting. There was little myelosuppression or thrombocytopenia on the day of starting a new course of therapy but the haemoglobin dropped by 2 g/dl in 32% of patients during therapy. Thus DMV is a relatively non-toxic active regimen for patients with advanced breast cancer.
对40例晚期乳腺癌患者给予口服二溴卫矛醇500毫克、静脉注射丝裂霉素C 10毫克和静脉注射长春碱10毫克的联合治疗，所有药物均在第1天给予，并每4周重复一次。除1例患者外，其他患者均接受过内分泌治疗。24例既往未接受过治疗的患者的缓解率（完全缓解+部分缓解）为66%，16例既往接受过治疗的患者的缓解率为37%。缓解者的生存期明显长于未缓解者。32%的患者出现恶心和呕吐。在开始新疗程治疗当天几乎没有骨髓抑制或血小板减少，但在治疗期间32%的患者血红蛋白下降了2克/分升。因此，DMV方案对晚期乳腺癌患者来说是一种相对无毒的有效治疗方案。
